Freneslerbart & MevonlerbartA Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07675811

Conditions

Allergic Conjunctivitis

Eligibility Criteria

Sex: All

Age: 8+

Healthy Volunteers: Not accepted

Interventions

REGN-2Cat

Freneslerbart

Mevonlerbart

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-08-12.